Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saifudin Hussein

Cardiovascular Disease Lanham, MD Medical Doctor

NPI 1306025739 CMS profile 104590

8116 Good Luck Rd Ste 305, Lanham, MD 20706

Open in the dashboard

General payments

$5,721

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Saifudin Hussein of Lanham, MD is reported in the CMS Open Payments database as having received $5,721 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,512 68
2024 General $1,253 48
2023 General $682 33
2022 General $913 50
2021 General $667 25
2020 General $194 10
2019 General $501 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saifudin Hussein
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Saifudin Hussein were reported at $1,512. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Saifudin Hussein Cardiovascular Disease median Middle half National median
2019 $501 $450 $127–$1,392 $163
2020 $194 $242 $77–$751 $114
2021 $667 $335 $101–$1,037 $132
2022 $913 $395 $121–$1,211 $149
2023 $682 $443 $136–$1,283 $160
2024 $1,253 $450 $136–$1,323 $164
2025 $1,512 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $587 33 payments
  2. E.R. Squibb & Sons, L.L.C. $575 31 payments
  3. Amgen Inc. $483 22 payments
  4. Abbott Laboratories $453 11 payments
  5. Pfizer Inc. $389 20 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $357 16 payments
  7. Merck Sharp & Dohme Corporation $349 20 payments
  8. AstraZeneca Pharmaceuticals LP $330 12 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $303 15 payments
  10. Novo Nordisk Inc $254 12 payments
  11. Other $1,641 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,609 245 payments
  2. Education $113 3 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $392 22 payments
  2. Confirm Rx $389 7 payments
  3. Repatha $365 17 payments
  4. VERQUVO $349 20 payments
  5. LEQVIO $303 14 payments
  6. LifeVest $303 15 payments
  7. VYNDAQEL $287 14 payments
  8. JARDIANCE $263 12 payments
  9. SAPIEN 3 Ultra RESILIA $189 1 payment
  10. CAMZYOS $184 9 payments
  11. Other $3,705 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,054

Median for Cardiology: 2,533

Drug cost

$244,252

Median for Cardiology: $485,213

Branded share of claims

19.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 106 $152,705
Entresto Sacubitril/Valsartan Brand 27 $33,240
Jardiance Empagliflozin Brand 16 $26,090
Farxiga Dapagliflozin Propanediol Brand 12 $12,080
Xarelto Rivaroxaban Brand 17 $12,016
Metoprolol Succinate Generic 126 $2,268
Atorvastatin Calcium Generic 117 $1,303
Amlodipine Besylate Generic 162 $944
Losartan Potassium Generic 51 $495
Nitroglycerin Generic 28 $476

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$343,291

Of which drugs: $1,415

Medicare patients

1,043

Average age 74

Services billed

4,715

626 women, 417 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 54%
Arthritis 47%
Chronic kidney disease 43%
Ischemic heart disease 38%
Heart failure 34%
Atrial fibrillation 29%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 68 272 $1,415

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $168
$168 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $151
$151 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $99
$99 16 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $91
  • PFIZER INC. $6
$96 106 —
VYNDAQEL
  • PFIZER INC. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record